S

SCYNEXIS
D

SCYX

1.10000
USD
-0.03
(-2.65%)
مغلق
حجم التداول
350
الربح لكل سهم
1
العائد الربحي
-
P/E
-1
حجم السوق
41,737,565
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    ADVM
    -0.03500
    (-0.88%)
    3.95000 USD
    A
    AEMD
    -0.01550
    (-2.58%)
    0.58640 USD
    A
    ALLO
    -0.07500
    (-3.33%)
    2.17500 USD
    B
    BTAI
    -0.22000
    (-9.36%)
    2.13000 USD
    R
    RIGL
    -0.730
    (-3.51%)
    20.090 USD
    V
    VXRT
    0.00670
    (0.95%)
    0.70980 USD
    المزيد
الأخبار
المقالات

العنوان: SCYNEXIS

القطاع: Healthcare
الصناعة: Drug Manufacturers - Specialty & Generic
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.